Q32 Bio (Q32 Bio) Accounts Payable : $4.96 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Accounts Payable?

Q32 Bio's Accounts Payable for the quarter that ended in Mar. 2024 was $4.96 Mil.

Q32 Bio's quarterly Accounts Payable increased from Sep. 2023 ($1.83 Mil) to Dec. 2023 ($3.47 Mil) and increased from Dec. 2023 ($3.47 Mil) to Mar. 2024 ($4.96 Mil).

Q32 Bio's annual Accounts Payable declined from Dec. 2021 ($2.68 Mil) to Dec. 2022 ($1.44 Mil) but then increased from Dec. 2022 ($1.44 Mil) to Dec. 2023 ($3.47 Mil).

Q32 Bio Accounts Payable Historical Data

The historical data trend for Q32 Bio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Accounts Payable Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable

2.68

1.44

3.47

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial			1.44	-	1.83	3.47	4.96

Q32 Bio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Q32 Bio Accounts Payable Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024